Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02310724 · ClinicalTrials.gov registry record
TODAY2 Phase 2 Follow-up
A clinical trial, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- 517
- Enrollment target
NCT02310724: Completed study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
NCT02310724 is a clinical trial that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 517 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02310724 has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- 517 participants
- Enrollment target
Study Summary
The primary objective of T2P2 is to track the progression of T2D and related comorbidities and complications in the TODAY cohort as they transition to young adulthood. We hypothesize that: * Youth-onset type 2 diabetes (T2D) will progress rapidly and result in high rates of diabetes-related medical complications and comorbidities. * The rapid rate of progression is related to increased insulin resistance characteristic of puberty, worse β-cell function, degree of glycemic control, control of non-glycemic factors, and obesity itself.
Primary Outcome
a microvascular complication determined by fundus photography
Interventions
- OTHER TODAY cohort
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 517 participants |
| Start Date | 2014-03-01 |
| Est. Completion | 2020-01-17 |
What the finished NCT02310724 record still lists
NCT02310724 is an observational study that tracks outcomes without assigning an intervention. The registered 517 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which TODAY cohort is the first listed.
NCT02310724 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02310724 about?
NCT02310724 is a clinical study titled "TODAY2 Phase 2 Follow-up". The primary objective of T2P2 is to track the progression of T2D and related comorbidities and complications in the TODAY cohort as they transition to young adulthood. We hypothesize that: * Youth-onset type 2 diabetes (T2D) will progress rapidly and result in high rates of diabetes-related medical...
What is the current status of trial NCT02310724?
This trial is currently completed. The enrollment target is 517 participants. The study started on 2014-03-01. Estimated completion is 2020-01-17.
What interventions are being tested in trial NCT02310724?
The interventions under investigation include: TODAY cohort (OTHER).
Who is sponsoring clinical trial NCT02310724?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05676450 · 517 participants · NA
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
- NCT04524871 · 518 participants · Phase 1
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
- NCT07112196 · 518 participants · Phase 2
Visugromab in Cachexia International Trial
- NCT05933083 · 516 participants · NA
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI